RingCentral heads into its October 22 third-quarter update with a clear operating test: whether a subscription-heavy revenue base can translate paid AI adoption into durable growth, margin discipline and cash generation. The June-quarter results offer a useful baseline without settling that question.
Second-quarter revenue was $657 million, including $634 million of subscription revenue. Subscription sales represented 96% of the total. RingCentral also posted GAAP operating income of $50 million. Its GAAP margin reached 7.7%, compared with 23.4% on a non-GAAP basis, and free cash flow totaled $180 million. Together, those figures frame a business whose next update will be judged on the relationship among growth, profitability and cash rather than any single headline.
AI adoption is the most visible open question. At the second-quarter release, customers using at least one paid AI product represented approximately 13% of annual recurring revenue. That is an adoption measure, not a direct statement of AI revenue. The October 22 discussion can add clarity by placing the metric beside reported subscription revenue, operating results and the full-year cash outlook.
The revenue mix provides another important lens. RingEX and RingCentral contact center offerings accounted for more than 90% of subscription revenue, while no individual customer represented more than 10% of annual revenue in 2025, 2024 or 2023. That combination points to product concentration without the same concentration in a single customer. Evidence on demand and product adoption will help show how resilient that mix remains.
Market conditions may amplify the reaction. RNG closed at $75.44 on October 16 after a 5.63% decline in that session, while QQQ had fallen 5.52% over five sessions. Those moves do not determine the operating result, but they raise the importance of complete, comparable figures. The key read will be whether revenue, margins, AI adoption and cash expectations tell a consistent story.
Read the full RingCentral premium review for the complete evidence, catalyst map and risk analysis.
Market analysis, not personalized investment advice.